Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/126473
Title: Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification
Author: Hsu, Sandy Chan
Sears, Renee L.
Lemos, Roberta R.
Quintáns, Beatriz
Huang, Alden
Spiteri, Elizabeth
Nevarez, Lisette
Mamah, Catherine
Zatz, Mayana
Pierce, Kerrie D.
Fullerton, Janice M.
Adair, John C.
Berner, Jon E.
Bower, Matthew
Brodaty, Henry
Carmona, Olga
Dobricić, Valerija
Fogel, Brent L.
García Estevez, D
Goldman, Jill
Goudreau, John L.
Hopfer, Suellen
Janković, Milena
Jaumà, Serge
Jen, Joanna C.
Kirdlarp, Suppachok
Klepper, Joerg
Kostić, Vladimir
Lang, Anthony E.
Linglart, Agnès
Maisenbacher, Melissa K.
Manyam, Bala V.
Mazzoni, Pietro
Miedzybrodzka, Zofia
Mitarnun, Witoon
Mitchell, Philip B.
Mueller, Jennifer
Novaković, Ivana
Paucar, Martin
Paulson, Henry
Simpson, Sheila A.
Svenningsson, Per
Tuite, Paul
Vitek, Jerrold
Wetchaphanphesat, Suppachok
Williams, Charles
Yang, Michele
Schofield, Peter R.
Oliveira, João R. M. de
Sobrido, María Jesús
Geschwind, Daniel H.
Coppola, Giovanni
Keywords: Genètica
Ganglis basals
Genetics
Basal ganglia
Issue Date: Feb-2013
Publisher: Springer
Abstract: Familial idiopathic basal ganglia calcification (IBGC) or Fahr's disease is a rare neurodegenerative disorder characterized by calcium deposits in the basal ganglia and other brain regions, which is associated with neuropsychiatric and motor symptoms. Familial IBGC is genetically heterogeneous and typically transmitted in an autosomal dominant fashion. We performed a mutational analysis of SLC20A2, the first gene found to cause IBGC, to assess its genetic contribution to familial IBGC. We recruited 218 subjects from 29 IBGC-affected families of varied ancestry and collected medical history, neurological exam, and head CT scans to characterize each patient's disease status. We screened our patient cohort for mutations in SLC20A2. Twelve novel (nonsense, deletions, missense, and splice site) potentially pathogenic variants, one synonymous variant, and one previously reported mutation were identified in 13 families. Variants predicted to be deleterious cosegregated with disease in five families. Three families showed nonsegregation with clinical disease of such variants, but retrospective review of clinical and neuroimaging data strongly suggested previous misclassification. Overall, mutations in SLC20A2 account for as many as 41 % of our familial IBGC cases. Our screen in a large series expands the catalog of SLC20A2 mutations identified to date and demonstrates that mutations in SLC20A2 are a major cause of familial IBGC. Non-perfect segregation patterns of predicted deleterious variants highlight the challenges of phenotypic assessment in this condition with highly variable clinical presentation.
Note: Versió postprint del document publicat a: https://doi.org/10.1007/s10048-012-0349-2
It is part of: Neurogenetics, 2013, vol. 14, num. 1, p. 11-22
URI: http://hdl.handle.net/2445/126473
Related resource: https://doi.org/10.1007/s10048-012-0349-2
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
HsuSC.pdf975.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.